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Abstract
Using positron emission tomography, we measured in vivo uptake of 18F-fluorodeoxyglucose (FDG) in the brain and heart of
C57Bl/6 mice at intervals across a 24-hour light-dark cycle. Our data describe a significant, high amplitude rhythm in FDG
uptake throughout the whole brain, peaking at the mid-dark phase of the light-dark cycle, which is the active phase for
nocturnal mice. Under these conditions, heart FDG uptake did not vary with time of day, but did show biological variation
throughout the 24-hour period for measurements within the same mice. FDG uptake was scanned at different times of day
within an individual mouse, and also compared to different times of day between individuals, showing both biological and
technical reproducibility of the 24-hour pattern in FDG uptake. Regional analysis of brain FDG uptake revealed especially
high amplitude rhythms in the olfactory bulb and cortex, while low amplitude rhythms were observed in the amygdala,
brain stem and hypothalamus. Low amplitude 24-hour rhythms in regional FDG uptake may be due to multiple rhythms
with different phases in a single brain structure, quenching some of the amplitude. Our data show that the whole brain
exhibits significant, high amplitude daily variation in glucose uptake in living mice. Reports applying the 2-deoxy-D[14C]-
glucose method for the quantitative determination of the rates of local cerebral glucose utilization indicate only a small
number of brain regions exhibiting a day versus night variation in glucose utilization. In contrast, our data show 24-hour
patterns in glucose uptake in most of the brain regions examined, including several regions that do not show a difference in
glucose utilization. Our data also emphasizes a methodological requirement of controlling for the time of day of scanning
FDG uptake in the brain in both clinical and pre-clinical settings, and suggests waveform normalization of FDG
measurements at different times of the day.
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Introduction
Positron Emission Tomography (PET) is a non-invasive and
quantitative nuclear imaging modality used for a range of clinical
diagnostic and pre-clinical experimental applications. PET often
employs 18F-fluorodeoxyglucose (FDG), a sugar molecule labeled
with the positron emitting radionucleotide 18F (110 minute half-
life), as the nuclear probe for imaging [1]. FDG is taken up by cells
and subsequently phosphorylated, but cannot be metabolized any
further [2], thus providing a measure of glucose uptake by cells.
This imaging technique provides functional information in
detecting tissues with high glucose demands such as the heart,
the brain, and many types of cancers. Scanning of the radiolabeled
glucose in a three dimensional space in living tissue is a powerful
tool in imaging the metabolic condition of a tissue of interest. PET
scanning is used in a wide array of pre-clinical and clinical settings
to investigate of diseases such as dementia, Alzheimer’s disease,
Parkinson’s disease, brain injury, stroke, coronary heart disease
and oncology [3–5]. As a matter of practicality, FDG is
synthesized during the early morning hours for usage by clinicians
and researchers during the daytime. Because of the short half-life
of the radionucleotide this introduces a peculiar dichotomy in
which human patients are imaged during their ‘‘awake’’ phase of
the day, while pre-clinical specimens like nocturnal mice are
imaged during their ‘‘sleep’’ phase, unless they are kept under
light-dark conditions that are different from the normal day
timing.
Many processes in physiology, vigilance state and cognitive
performance are widely observed to show daily (or ‘diel’) variation.
This daily pattern can be driven by homeostatic processes in
physiology (e.g. tiredness, hunger) and/or by cues from the
external environment (e.g. changes in activity pattern due to
environmental light-dark conditions or social obligations). When
the daily rhythms in variation persist under constant conditions,
they are said to be ‘circadian’ (,24 hour), and these circadian
rhythms are driven by internal clocks. A biological clock, located
in the brain, is synchronized (entrained) by the environmental
light-dark (LD) cycle, and coordinates the anticipation of many of
these daily, rhythmic processes through transmitting timing
information to a hierarchy of clocks in the central nervous system
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(CNS) and peripheral clocks [6]. This principal light entrainable
clock in mammals is located in the suprachiasmatic nuclei (SCN)
of the hypothalamus and drives rhythms in behavior and
physiology [7].
Quantifying temporal glucose utilization of brain regions has
been made possible in terminal experiments using the 2-deoxy-
D[14C]-glucose (2-DG) method originally described by Sokoloff
et al. [8]. Diurnal rhythmicity in glucose utilization in the SCN has
been reported to be high during the day across mammalian
species, including night active, day active and bimodal/crepuscu-
lar animals (e.g. mouse [9], opossum [10], rat, monkey and cat
[11]). Also in birds, the visual SCN shows rhythmic 2-DG uptake,
peaking during the subjective day (House sparrow [12] and
chicken [13]) under both LD and constant darkness (DD)
conditions. The rhythm in SCN glucose metabolism is related to
SCN function (see [14]) and is in antiphase with rhythms of
glucose uptake or utilization observed in other brain regions.
In addition to the SCN, many structures in the CNS have been
found to show daily profiles in expression of one or more clock
genes ([15] and referenced therein for central, extra-SCN
oscillators). While cells and tissues can show clock gene expression
with daily patterning, this does not mean that they are self-
sustained oscillators, and expression can be driven by rhythmic
processes. Using the 2-DG method throughout the brain, Crane
et al. [16] reported a 24-hour variation in cortical glucose
utilization in rats with a higher utilization during dark than light,
showing peak values during the night phase (Zeitgeber Time [ZT]
15; ZT 0 is lights on and ZT 12 is lights off). When looking at the
quantitation of glucose utilization in different brain structures of
female mice using the 2-DG method, 8 out of 60 structures
identified showed significantly lower glucose utilization between
ZT 6–8 compared to ZT 18–20 [9]. Similarly in freely moving
rats, glucose utilization as quantified using the 2-DG method
revealed a day-night variation with increased glucose utilization in
17 out of 144 brain structures in the first 4 hours of the dark phase
of the LD cycle [17]. In both studies, only one brain structure, the
SCN, showed significantly higher levels of glucose utilization
during the daytime phase [9,17]. Karaganis et al. [18] showed that
the diurnal leghorn chicken shows peaks in 2-DG uptake in the
telen- and diencephalon during mid, to late day (peaking at ,ZT
8) under LD cycle conditions, but this was not observed in DD.
These authors also showed a rhythm in heart and liver 2-DG
uptake, with peaks in the dark phase, liver peaking around ZT 17
and heart around ZT 15. Peripheral rhythms in 2-DG uptake did
not persist in DD, when rhythmicity is self-driven, as opposed to
driven by the external LD cycle.
Energy utilization of central tissues is to a large extent attributed
to action potentials and postsynaptic potentials [19]. Energy
demands of the brain account for up 20% of the standard
metabolic rate of the whole body [20] and thus it utilizes a large
proportion of the circulating blood glucose. The daily rhythm in
activity and inactivity of numerous processes in physiology and
behavior driven by the CNS leads to the hypothesis that the brain
utilizes glucose in a pattern that shows a high daily amplitude. The
autoradiographic 2-deoxy-D[14C]-glucose method of Sokoloff et al.
[8] is very effective in the quantitative determination of the rates of
local cerebral glucose utilization, but does not present a uniform,
within individual pattern of underlying brain glucose uptake, and
where uptake reflects the energy demand that effectively needs to
be met by the cells.
The heart is among the higher oxygen consuming tissues [20]
and is visible on PET scans as a major organ of FDG uptake. A
temporal profile with an early morning peak in acute coronary
heart disease and cardiac death is observed [21] and expression of
the molecular components of the clock is apparent in cardiomy-
ocytes and persists independently in an in vitro culture [22,23],
indicating a functional clock mechanism. Indeed, Young and
colleagues [24] found that rat hearts had higher carbohydrate
oxidation, contractile function and output during the middle of the
dark phase of the LD cycle as compared to the middle of the light
phase. Moreover, in the same study in rats, gene expression for the
GLUT1 and GLUT4 glucose transporters was up regulated in the
early dark phase, which is the active phase for these nocturnal
animals.
Previous measurements using the 2-DG method only report on
site-specific (as opposed to whole individual) glucose utilization
and not uptake from the glucose stores in the circulating blood in
real-time. Additionally, quantifications of glucose utilization were
made at one time point only for each individual animal. Using
PET, we can measure glucose uptake in whole brain and heart in
living mice throughout the 24-hour LD cycle, including multiple
measurements in a single animal. PET is increasingly applied in
rodent models and in clinical applications [5] and daily variation
in brain glucose uptake may mask some of the results found.
Given that mouse models of disease are intended to mirror those
taking place in humans, we sought to determine if the
synchronization of FDG-PET imaging with circadian biology
would result in signal variation from relevant tissues in mice. Thus,
we have employed PET imaging on C57Bl/6 mice at multiple
times of day within and between individuals to interrogate the
effects of daily rhythms on FDG uptake in brain and heart tissue.
Using this method we show strong time-of-day specific variation in
glucose uptake at the level of the whole brain and variant
amplitudes in different brain regions. Additionally, we show that
heart glucose uptake in the same animals does not show such
rhythmicity, but shows high variability throughout the 24-hour
day. These data show a much larger scale of 24-hour variation in
glucose demand than would be expected from previously reported
glucose utilization studies using the 2-DG method. It also indicates
that for both clinical and pre-clinical/experimental applications of
PET scanning, time-of-day of measurement is an important
variable that must be considered.
Results
The left frames of Figure 1 show a 3-dimensional reconstruction
of merged X-ray computerized tomography (CT, greyscale) and
PET (color scale) images of a mouse at the middle of the dark
phase of the LD cycle. The PET shows the high localization of
(18F) fluorodeoxyglucose (FDG) in the brain and heart. The right
panels in Figure 1 show representative images of individual mice at
4 times during the 24-hour LD cycle used for glucose uptake
measurements. When multiple measurements were made within
one mouse, they are included. Mean age at the time of
measurement was 92 days (SEM=5 days) and was not different
between animals measured at different times of day (proc mixed
P.0.05). Both for brain and heart tissue, there was no effect of sex
of the animal on the total FDG uptake (proc mixed, P’s.0.05).
Mean volumes in the region-of-interest were 0.462 (SEM=0.005)
cubic centimeter (ccm) for the brain and 0.230 (SEM=0.013) ccm
for the heart, and these volumes did not differ between time-of-day
or sexes (proc mixed P’s.0.05).
Total FDG uptake in the brain differed significantly between
different times of day (proc mixed, P,0.001). Figure 2a shows
individual values for whole brain FDG uptake throughout the
day. Whole brain FDG uptake centered around the mid of the
dark phase of the LD cycle (ZT 18), are significantly increased, to
150% of the average of the other time points (Proc mixed, least
Time-of-Day PET-FDG Profiling of Brain and Heart
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square means contrast: P,0.005, P,0.001 and P,0.001 with
ZT 6, ZT 12 and ZT 24/0 respectively, Figure 2b). The within
individual comparisons are shown in Figure 2c and confirm that
brain FDG uptake measurements, taken at ZT 18 and ZT 24/0
within the same mouse, differed significantly (paired t-test;
P,0.005). No difference is seen for within-individual measure-
ments of brain FDG uptake centered on ZT 6 and ZT 12 (paired
t-test; P.0.05).
In contrast to whole brain FDG uptake, heart FDG uptake
shows no time-of-day difference (Figure 3a; proc mixed, P.0.05).
Variability of heart FDG uptake was much larger than whole
brain FDG uptake (compare Figure 2a to Figure 3a), and mean
heart FDG uptake was similar for each of the four time points
(Proc mixed, least square means contrast: P’s.0.05; Figure 3b).
Within individual comparison of heart FDG uptake confirmed no
time-of-day variation between measurements centered on ZT 18
vs. ZT 24/0 and ZT 6 vs. ZT 12 (paired t-test, P’s.0.05;
Figure 3c).
Regional measurements of brain FDG uptake were established
using a PET specific, mouse brain template. The regional
mapping was validated through the correlation between a) the
total FDG uptake as established by CT based volume-of-interest
construction and b) the summation of the regional uptakes
(Pearson R2 = 0.71; Figure S2). All brain regions, except the brain
stem, showed significant variation in FDG uptake (average of
voxel) over time (Proc mixed, a=0.05; Figure 4). While all
measured brain region, apart from the brain stem, showed
peaking FDG uptake at ZT 18 (see Figure S3), the peak-to-trough
amplitude of the nocturnal variation differs between the brain
regions. Most tissues exhibited amplitudes in FDG uptake around
the average (within one standard deviation), with some excep-
tions. The olfactory bulb and cortex show ‘above average’
amplitudes, while the amygdala and hypothalamus show ‘below
average’ amplitudes. The brain stem showed the lowest
amplitude, which confirms the absence of a statistically significant
temporal variation in FDG uptake throughout the day. Total
uptake (average uptake x volume (ccm)) for each of the brain
regions is shown in Table 1.
Discussion
Using positron emission tomography across the 24-hour day, we
show that FDG uptake in the whole brain in living mice exhibits a
nocturnal peak. Other studies have identified day-night or daily
differences in 2-DG quantified glucose utilization in a relatively
small number of brain regions, most with high glucose utilization
during the dark phase of the LD cycle [9,16–17]. Here, our in vivo
data show strong 24-hour variation in FDG uptake within
individual mice as determined by quantitative measurements in
the brain. Although the brain structures are not always
comparable due to different resolutions of the techniques (e.g.
the ‘thalamus’ in our study is represented by 19 discrete nuclei in
[17] of which only one is reported as showing a day-night
difference, and 7 nuclei in [9] of which 4 show a difference), taken
together these data indicate that while glucose uptake shows a 24-
hour pattern in most brain regions, this pattern in uptake may not
necessarily lead to a similar pattern in glucose utilization. For
many rodent PET studies, the time-of-day of scanning and LD
conditions are not strongly controlled variables, or not reported.
One implication of our data is that not controlling for the time-of-
day of scanning may result in a bias, within the range of
physiologically relevant findings.
The within individual comparison is, to our knowledge, the first
time brain glucose uptake in mice has been measured in such a
time informed method. For the ZT 18 to ZT 24/0 comparison, all
individuals show a decrease in FDG uptake. Strikingly, for the ZT
6 to ZT 12 comparison, all mice but one exhibit a drop in absolute
brain FDG uptake. While this numerical drop in FDG uptake at
the light to dark transition does not reach statistical significance, it
appears rather consistent within the individual animal analysis,
Figure 1. Fused CT and PET images from individual representative C57Bl/6 mice. The left panel shows a 3D reconstruction of a mouse
measured in the middle of the dark phase of the light-dark cycle, where brain, heart and bladder show high FDG uptake. Both kidneys and the
interscapular brown adipose tissue are also visible. Colors indicate only mid-range FDG uptake, where green is lower and red is higher uptake. On the
right, representative individuals from the 4 groups measured at (from left to right) ZT6, 12, 18 and 24/0 are depicted. Images are shown for sagittal
(top), coronal (middle) and transverse (bottom) planes. Scale bars belonging to the right panel for CT intensity (represented as gray-scale) and FDG
uptake (in color) are shown on the bottom left.
doi:10.1371/journal.pone.0031792.g001
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and may indicate that even minor aspects of the overall profile are
still consistent. Animals were awake during FDG uptake and alive
during PET scanning, and an unanaesthetized state has been
shown to increase brain FDG uptake [25].
Differences are noted in the amplitudes of the 24-hour variation
in FDG uptake in different brain regions. The SCN of the
hypothalamus, containing the major circadian oscillator, is the
only brain region reported in nocturnal rodents to show elevated
Figure 2. Time-of-day specific analysis of FDG uptake in brain. (A) Whole Brain FDG uptake in C57Bl/6 mice (N= 37) plotted at the time of
measurement. The dashed line is a smoothed spline curve through group averages. Both group averages (B) and within individual comparisons at
different times of day (C) of total brain FDG uptake showed significantly higher uptake at the middle of the active phase at ZT 18. Error bars indicate
SEM. * = Proc mixed, least square means contrast: P,0.005, P,0.001 and P,0.001 with ZT 6, ZT 12 and ZT 24/0. #=Paired t-test P,0.005.
doi:10.1371/journal.pone.0031792.g002
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glucose utilization as quantified using the 2-DG method during the
light phase rather than during the night [9,14,17]. While the
spatial resolution and ‘partial voluming effect’ [26] of our
technique is not sufficient to identify brain regions on such a
small scale, the below-average amplitude in the hypothalamus is
indicative of an antiphase rhythm specifically in the SCN, that
would quench the rhythmic profile expressed in the remaining
hypothalamic nuclei. The low amplitude in both left and right
amygdaloid FDG uptake may again be caused by rhythms in
specific amygdaloid nuclei exhibiting different peak phases. This
Figure 3. Time-of-day specific analysis of FDG uptake in heart. (A) Whole heart FDG uptake in the same C57Bl/6 mice as Figure 2 (N= 37)
plotted at the time of measurement. There is no statistically significant variation of total FDG uptake for grouped averages (B). The within individual
comparison (C) also shows no uniform FDG uptake at different times of the day.
doi:10.1371/journal.pone.0031792.g003
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would be consistent with clock protein expression in rats being
rhythmic in an antiphase relationship in the central nucleus of the
amygdala and the basolateral amygdala [27].
Our regional analysis shows a comparatively large amplitude in
average FDG uptake in the olfactory bulb, together with an overall
average high uptake at all phases of the 24-hour cycle. Although a
day-night variation in glucose utilization has been reported in the
nucleus of the olfactory tract of the mouse [9], to our knowledge
such a strong daily variation in glucose utilization of the olfactory
bulb of the mouse has not been reported in previous studies in
using the 2-DG method. The olfactory bulb can show in vivo and in
vitro (SCN independent) rhythms in expression of the clock gene
period1, as reported by a bioluminescent reporter in rats [28,29].
This in contrast to other brain nuclei that show a larger
dependency on signals derived from the SCN. Olfactory
stimulation enhances light-induced responses in both transcrip-
tional activity in the SCN and behavioral entrainment to a new
LD cycle [30]. In our study, respiration anesthetics may have
activated the olfactory bulb (in line with high overall uptake). Such
activation would have been given at all times sampled and
therefore did not introduce a 24-hour signal in itself. Indeed, it is
feasible that this pattern is not visible in terminal experiments due
to an absence of direct stimulation and the use of respiration
anesthetics may have emphasized the intrinsic 24-hour pattern in
the olfactory bulb not visible in other glucose uptake measure-
ments.
Treatment of mice with 30 minutes of light of high intensity
(only effects are shown for a reported intensity of a 1000 lux)
induced period gene expression in the olfactory bulb itself [31].
There are SCN independent circadian rhythms in cedar oil
Figure 4. Amplitude of total FDG uptake in specific brain regions. All brain regions, except the brain stem, show significant variations with
time (Proc mixed, a= 0.05). The dashed line indicates the average and gray area indicates average 6 standard deviation.
doi:10.1371/journal.pone.0031792.g004
Table 1. Total 18F-FDG uptake in brain regions.
Brain region
Total uptake
(SUV [e205 (g/ml)*ccm])
Cortex 23.4260.87
Cerebellum 7.7560.32
Brain stem 6.3360.29
Olfactory bulb 4.2960.18
Thalamus 4.0560.17
Left striatum 2.0660.07
Right striatum 2.0160.07
Left hippocampus 1.8560.08
Right hippocampus 1.7260.07
Basal Forebrain 1.7260.06
Superior colliculi 1.3260.05
Hypothalamus 1.2760.05
Right mid brain 1.2060.05
Right amygdala 0.6960.03
Central gray 0.6160.03
Right inferior colliculi 0.5660.02
Left amygdala 0.5660.02
Left mid brain 0.3360.01
Left inferior colliculi 0.2260.01
doi:10.1371/journal.pone.0031792.t001
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induced c-FOS expression in the olfactory bulb and more
interestingly, lesions of the mouse olfactory bulb shortened the
period length of free running behavioral rhythms measured in DD,
and a concordant enhancement of phase advances of the clock in
the SCN, as inferred from behavioral rhythms [32]. Because of
these data, it has been suggested that the olfactory bulb contains
an independent, self-sustaining pacemaker. Our data highlights a
strong 24-hour pattern of glucose uptake in the olfactory bulb and
could support an important role for olfactory stimulation in the in
vivo entrainment of the olfactory bulb clock specifically, as well as
downstream entrainment of the SCN clock.
Heart rate changes can be rapid and heart rate is correlated to
oxygen consumption and metabolic rate [33]. In response to an
immediate increase in heart workload, glucose and lactate
oxidation increases rapidly [34]. The absence of a 24-hour
rhythm in FDG uptake is in contrast to the study by Karaganis
et al. [18] on the diurnal chicken that revealed a nocturnal peak in
glucose uptake in the heart as assessed by 2-DG autoradiography.
Our data may simply reflect the rapid autonomic control of heart
rate, which could be due in part to our paradigm, which
subsequently affects FDG uptake (e.g. [35]). Balb/c mice show
lower brain FDG uptake and higher heart FDG uptake when
anesthetized with isoflurane during injection of the tracer and
recovery [36]. Also in immunocompromised mice (C.B.-17 Scid/
Scid strain), FDG uptake by the myocardium was increased by
isoflurane anesthesia [37]. In our protocol, we have not kept the
mice under isoflurane anesthesia during the interval between
injection and scanning, and this may have benefited brain FDG
uptake over heart FDG uptake. As a result, the signal to noise ratio
in heart FDG uptake may have increased, resulting in large inter-
individual variability and lower likelihood of finding time-of-day
specific variability. Also, in humans, plasma glucose levels have
been shown to affect myocardial FDG uptake. Fasting before
imaging decrease plasma FDG clearance rates and decreases
myocardial FDG uptake [38], but can also result in larger
variability [39,40].
The brain cannot store large amounts of glucose, and is largely
dependent on blood glucose levels to supply energy sources. In
rodents, plasma glucose levels show circadian variation, peaking
around the time of early activity in the dark phase in the rest-
activity cycle, which is independent of feeding rhythms [41–43].
The rhythm in glucose availability shows strong dependence on
the SCN (see [44]), and also the peripheral clock in the liver has
been shown to be involved in glucose homeostasis [45]. While
skeletal muscle is commonly accepted as the largest glucose
utilizing tissue, the brain is also a large glucose metabolizing tissue.
The brain is often reported to use a large portion of the available
glucose, in the range of 25% of total body glucose utilization in
humans [46,47], and is responsible for approximately 20% and
3% (in humans and rats, respectively) of resting metabolic state
[20]. Our data represent a measure of glucose uptake, and caution
is warranted in extrapolating these measures to brain glucose
utilization. The similarities in the peak timing of brain glucose
uptake and blood glucose availability is intuitive, but may also
indicate a potential vulnerability of the brain to alterations in the
circadian profile of blood glucose concentration. It may be
functionally related that restricting food to certain times of the day
only affects the food entrainable oscillator and not the SCN, while
caloric restriction alters SCN entrainment (for review see [48]).
What are the functional correlates of the daily variation in
glucose uptake in the brain? Indeed we know that central self-
sustained clocks (e.g. the master pacemaker located in the SCN of
the hypothalamus), and driven oscillations in clock gene expression
can regulate many rhythmic processes in biochemistry, physiology
and behavior allowing anticipation of environmental changes
[6,7]. Sustaining these anticipatory rhythms and the processes they
drive undoubtedly requires energy. Electrical activity of the brain
shows wake-dependent and circadian modulation in humans [49],
and there is substantial evidence that cognitive performance is
subject to circadian modulation [50]. Also, our 24-hour variation
in vigilance will affect brain activity and metabolism. The daily
variation in brain metabolic activity is made up of two groups of
processes that can vary with the time of day; diurnal variation in
processes driven by the brain itself, and processes that are driven
by other aspects of physiology that demand brain activity.
In summary, our data show strong in vivo 24-hour patterns in
overall brain glucose uptake, peaking in the mid-dark phase, which
is the active phase for the nocturnal mouse. Daily patterning is
apparent in almost all brain regions, but there is heterogeneity in
terms of amplitude, possibly resulting from sub-brain region
dynamics. These data, first of all, underline the importance of
controlling for the time-of-day of PET scanning during studies of
the CNS. A practical implication for clinical oncology of a daily
rhythm in brain FDG uptake could be a decrease of ‘biological
variation’ through standardization, or temporal waveform nor-
malization of FDG measurements. Previous studies using the 2-
DG method have shown that a relatively small number of brain
structures exhibiting a day-night difference in glucose utilization,
whilst our data show a daily 24 hour pattern of underlying glucose
uptake in almost all brain regions identified. Our data describe a
significant, high amplitude daily rhythm in glucose uptake
throughout the brain, which is reproducibly observed within
individual animals.
Materials and Methods
Animals and experimental protocol
Mice were kept in light-tight cabinets which were climate
controlled (19–21uC, 60–70% humidity), and food and water were
available ad libitum. Male (N=6) and female (N=13) adult C57Bl/
6 mice were bred at the University of Notre Dame and housed
with littermates, and mice were randomly assigned to one of four
groups (N= 4–5 per group). Each group was entrained to a
12 hour light:12 hour dark (12:12 LD) cycle for at least 3 weeks,
where LD cycles for two groups were 12 hours out of phase with
the LD cycles of the other two groups (lights on at 03:00 AM and
15:00 PM respectively). On the day before measurement, mice
were individually housed and food was removed at least 5 hours
before the time of scanning. Longitudinal dual-modality CT and
PET scanning has been employed for over 10 years [51] and has
minimal effect on mouse health under our experimental
conditions, and all experiments were approved by the University
of Notre Dame Animal Care and Use Committee. Experiments
were performed in accordance with NIH Guidelines for the Care
and Use of Laboratory Animals.
Schedule 1 was aimed at measuring FDG uptake over a 24-
hour period, centered around 4 time points (lights on, mid-light,
lights off and mid-dark). Animals were 6463 (SEM) days of age at
the time of measurement. Two groups of mice that were entrained
to LD cycles that were 12 hours out of phase were measured on
the morning of one day, and the other two groups were measured
on the afternoon of a second day. On both days, mice from the
two anti-phase groups were measured in alternating order,
20 minutes apart. Measurement times were chosen such that
group mean measuring times were Zeitgeber Time (ZT [time of
lights on is ZT 0]) 06:15 (600:59 hours), ZT 12:10 (600:54), ZT
18:08 (601:04) and ZT 23:50 (600:54) (see Figure S1a). These
Time-of-Day PET-FDG Profiling of Brain and Heart
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groups will be referred to as ZT 6, ZT 12, ZT 18 and ZT 24/0
respectively.
Schedule 2 was aimed at testing reproducibility between, and
within individuals. The 2 groups of mice that were measured at
ZT 6 and ZT 18, we re-mixed into two groups and re-entrained to
the LD cycles. Measurements were made centered around light
and dark, and 10 days later, in the same mice, centered on mid-
light and mid-dark (see Figure S1b).
PET data acquisition and analysis
Mice were measured with 20 minute intervals, alternating mice
between two groups entrained to LD cycles 12 hours apart. Mice
were anesthetized with 1.5% isoflurane in an induction box, and
retro-orbitally [52,53] injected with ,200 mCI (Mean= 201.4,
SEM=1.4) of (18F) fluorodeoxyglucose (FDG [Spectron MRC,
South Bend, IN, USA]). Mice that were injected in the dark phase
of the LD cycle were briefly exposed to #5 minutes of light during
the injection procedure and were subsequently placed back into
the dark. The clock only fully resets after 2 hours but not start
before 1 hour after the initiation of the light pulse [54], and the
light is thus unlikely to have influenced the subsequent 30–
45 minutes of FDG uptake and PET scanning. After injection,
exactly 30 minutes were allowed for FDG uptake, before scanning
started. Within one minute after FDG injection mice recovered
from anesthesia, and mice did not receive anesthesia during the
FDG uptake period. Prior to scanning, mice were again
anesthetized with isoflurane and placed inside the scanner,
secured in a tooth bar. X-ray computed tomography (CT) and
Positron emission tomography (PET) images were acquired in an
Albira scanner (Carestream Health, Rochester, NY, USA). High
density PET (voxel size 0.6560.6560.944 mm [xyz]) and CT
(voxel size 250 Hounsfield units) images were reconstructed and
regional FDG uptake was quantified in PMOD version 3.2
(PMOD technologies, Zurich, Switzerland).
For the brain, the volume-of-interest was determined using the
scull outline of individual mice in the CT images and FDG uptake
was quantified from the reconstructed, and fused PET images.
Measures of localized FDG uptake in pre-defined brain regions
was obtained through applying a mouse brain template directly to
the PET image. In short, the acquired PET image of the mouse
was masked such that only the head portion was available and the
image was manually co-registered with the general PET mouse
brain mask available in the PMOD program. The PET image was
then normalized to the mask using PMOD 9.2 normalization
algorithms, and overlaid with the mouse brain template [55,56].
Individual amplitude of regional FDG uptake was expressed as the
difference between the lowest and highest mean voxel values. The
amplitudes were categorized in three groups, an above average, an
intermediate group that encompasses amplitudes with the range of
the mean 61 standard deviation, and a below average group.
Heart FDG uptake was determined from PET images using the
region-of-interest assessed from the PET directly.
FDG uptake was expressed as Standard Uptake Values (SUV
[g/ml]), accounting for body mass and minor variations in injected
dose. For assessing time-of-day differences, data of schedule 1 and
2 were combined. Because of the non-equidistant nature of the
sampling, data was binned in four groups centered on ZT 6,
ZT12, ZT 18 and ZT 24/0.
Statistics
Time-of-day effects were tested by fitting mixed linear models,
accounting for repeated measurements when applicable (proc
mixed, SAS version 9.2 [SAS Institute, Cary, NC, USA]) with
post-hoc least square means (LSMEANS) contrast analysis. Within
individual differences in schedule 2 were tested using paired t-tests
(proc t-test, SAS version 9.2). For all statistical analysis a cutoff of
p,0.05 was applied.
Supporting Information
Figure S1 Graphical representation of the layout of the
experiment, indicating two schedules. Schedule 1 was
aimed to measure FDG uptake, centered around 4 time points.
Schedule 2 was aimed at testing reproducibility between, and
within individuals.
(TIF)
Figure S2 Correlation between total FDG uptake estab-
lished through CT-based brain region-of-interest and
summation of all regional brain FDG uptake values. The
line indicates the linear regression. The spearman rank correlation
(R2 = 0.71) indicates the correlation between the two methods.
(TIF)
Figure S3 FDG uptake in specific brain regions. All brain
regions, except the brain stem, show significant variations with
time. Graphs are sorted left to right, top to bottom, in order of
above average to below average amplitude of the rhythm. P values
indicate the significance value for time-of-day specific effects.
(TIF)
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